Onkológia 2/2016
Nintendanib – new triple inhibitor of angiokinases in 2nd line of NSCLC
Nintedanib is potent novel tyrosine-kinase inhibitor that targets the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) signalling pathways. In the EU, nintedanib in combination with docetaxel is indicated for adults with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. Nintedanib is the first antiangiogenic agent to have shown a survival benefit in the second-line treatment of these patients.
Keywords: adenocarcinoma, NSCLC, nintedanib, angiogenesis, second-line treatment
